Recently, increasing research has demonstrated that CD59 is highly expressed in various forms of malignant tumor, including breast, prostate and gastrointestinal cancer, suggesting that CD59 is closely associated with tumor progression [46, 47]. This evidence concerns the gene CD59 and neoplasm.